A database of FDA approved therapeutic peptides and proteins
ID1260 | ThPPIDTh1037 | NameBotulinum Toxin Type B | Peptide SequenceMPVTINNFNYNDPIDNNNII Full view | Length255 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandMyobloc | CompanySolstice Neurosciences | Physical AppearanceClear and colorless to light-yellow sterile injectable solution | Route of AdministartionInjection | CategoryAntidystonic Agents | TargetVesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
ID1261 | ThPPIDTh1037 | NameBotulinum Toxin Type B | Peptide SequenceMPVTINNFNYNDPIDNNNII Full view | Length255 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandNeurobloc | CompanySolstice Neurosciences | Physical AppearanceClear and colourless to light yellow solution | Route of AdministartionIntramuscular Injection | CategoryAntidystonic Agents | TargetVesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
ID1419 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandBOTOX | CompanyAllergan | Physical AppearanceSterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strainClostridium botulinum type A | Route of AdministartionIntramuscular, intradetrusor and intradermal use | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1420 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandDysport | CompanyIpsen Pharmaceuticals | Physical AppearanceSterile vial for reconstitution | Route of AdministartionIntramuscular Injection | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1421 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandXeomin | CompanyMERZ AESTHETICS | Physical AppearanceSterile white to off-white lyophilized powder after reconstitution with preservative-free 0.9% Saline for Injection. | Route of AdministartionIntramuscular Injection | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1534 | ThPPIDTh1113 | NameGlatiramer Acetate | Peptide SequenceEAYKAAEKAYAAKEAAKEAA Full view | Length52 | Functional ClassificationIIa | DiseaseNeurological Disorder | BrandCopaxone | CompanyTeva Pharmaceutical Industries | Physical AppearanceClear, colorless to slightly yellow, sterile, nonpyrogenic solution | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetN.A. |
ID1812 | ThPPIDTh1203 | NamePeginterferon beta-1a | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseNeurological Disorder | BrandPlegridy | CompanyBiogen Canada Inc | Physical AppearanceSterile Solution | Route of AdministartionSubcutaneous | CategoryNA | Target |